Rethinking Treg Therapy Design to Incorporate Immune Reset Lymphodepletion & Enhance Self-Renewal & Persistence
11:30 am - Wednesday 24th March 2027
- Identifying committed Treg precursor populations that may complement conventional Treg therapies to achieve more durable immune tolerance
- Engineering Tregs to withstand CD3-directed depletion and unlock new conditioning strategies for cell therapy
- Assessing how evolving standards of care in Type 1 diabetes are reshaping trial design and the positioning of next-generation Treg therapies